TRDA (Entrada Therapeutics) Float Percentage Of Total Shares Outstanding: 64.34% (As of Jun. 30, 2026)


TRDA Entrada Therapeutics Inc TRDA
23 GF Score
Price $7.60
GF Value $0.92
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Entrada Therapeutics Float Percentage Of Total Shares Outstanding?

Entrada Therapeutics TRDA -1.43% 23 Float Percentage Of Total Shares Outstanding is 64.34% as of Jun. 30, 2026. GuruFocus rates TRDA with a GF Score™ of 23/100 and a GF Value™ of $0.92 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Entrada Therapeutics's float shares is 24.98 Mil. Entrada Therapeutics's total shares outstanding is 38.82 Mil. Entrada Therapeutics's float percentage of total shares outstanding is 64.34%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Entrada Therapeutics's Insider Ownership is 3.15%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Entrada Therapeutics's Institutional Ownership is 74.31%.

TRDA
23GF Score
Entrada Therapeutics Inc TRDA
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Entrada Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Entrada Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=24.98/38.82
=64.34%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 64.34% mean?
Entrada Therapeutics (TRDA) has a Float Percentage Of Total Shares Outstanding of 64.34% as of Jun. 30, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Entrada Therapeutics and its competitors.
Is Entrada Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Entrada Therapeutics' current Float Percentage Of Total Shares Outstanding is 64.34%. Overall, Entrada Therapeutics has a GF Score™ of 23/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Entrada Therapeutics' Float Percentage Of Total Shares Outstanding compare to NMRA and MGNX?
Entrada Therapeutics' Float Percentage Of Total Shares Outstanding of 64.34% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Entrada Therapeutics and its competitors. Entrada Therapeutics's current Float Percentage Of Total Shares Outstanding is 64.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Entrada Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Entrada Therapeutics (TRDA) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.92, compared to a current price of $7.60 — trading 726.1% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 64.34%. Entrada Therapeutics' overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Entrada Therapeutics (TRDA), the current Float Percentage Of Total Shares Outstanding is 64.34% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Entrada Therapeutics (TRDA) Overvalued in 2026?

Based on GuruFocus' analysis, Entrada Therapeutics stock appears to be overvalued. The current stock price of $7.60 is trading 726.1% above its estimated GF Value™ of $0.92. GuruFocus considers Entrada Therapeutics to be Significantly Overvalued.

Key valuation signals for TRDA:

  • Float Percentage Of Total Shares Outstanding: 64.34%
  • GF Value™: $0.92 vs. price of $7.60 (726.1% above fair value)
  • GF Score™: 23/100 with 4 warning signs

No single metric tells the full story. See the TRDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Entrada Therapeutics Business Description

Address One Design Center Place, Suite 17-500, Boston, MA, USA, 02210
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
23GF Score

Get the complete analysis for TRDA

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.60
Price
$0.92
GF Value